<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190915044771N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-03-04</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Analgesic efficacy of transdermal patches versus oral tablets on pain control of orthodontic patients</public_title>
      <acronym></acronym>
      <scientific_title>Analgesic efficacy of diclofenac and ketoprofen transdermal patches versus ibuprofen oral tablets on pain control after initial arch wire placement in orthodontic patients -a randomized clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75633</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Method of randomization: block
Unit of randomization: stratified
Randomization strata: sex, drug
How the random sequence was built: permutation
Allocation concealment: all the drugs will be packed in same unclear sealed envelops which is not distinguishable for the researcher. This process will be  done by a third person that is unaware of the object and protocol of the study.

complete explanation of Randomization:
Based on Stratified Permuted Blocks, all the patients who agreed to participate in the research will be randomly assigned a drug envelope that contains the studied drugs and their usage method. This operation will be performed by the therapist's assistant.
Since 48 patients will enter the randomization process and the variables of gender and type of drug are considered as criteria for classification, the patients will divided into 3 groups of 16 (8 males and 8 females).
A, B, C will be labeled on the envelopes.
48 envelopes will divided into two groups, blue and red. If the client is a woman, the red envelope will pickup, and if the client is a man, the blue envelope will be prescribed.
The envelopes will be filled with drugs and how to use them according to the order of the following three-number blocks based on the sequence of simple randomization.
Blue envelopes:
ABC, ACB, BAC, BCA, CBA, CAB, ABC, ACB
Red envelopes:
CAB, CBA, ABC, ACB, BAC, BCA, ABC, ACB

In order to hide the random allocation, the method of Sequentially numbered, sealed opaque envelopes which is abbreviated as SNOSE will be used, Blinding description: Patients do not become blind due to the prescription of different drugs; But since they do not meet each other, they will not understand the difference of prescription drugs.
In this study, the therapist (orthodontist), researcher and statistical analyst will not be aware of randomization and the drugs prescribed for the patients.
Only the therapist's assistant (allocating samples to groups) is aware of the prescription drug by coding the drug packages and registering them.
Patients will communicate only with the therapist's assistant, they will send him their pain level form after taking the drugs and ask him any questions.</study_design>
      <phase>4</phase>
      <hc_freetext>pain after initial arch wire placement in orthodontic patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1:  Name of the drug: Ketoprofen, How to use: Skin patch (patches with the trademark Kefentech from jeil health science company), Patch concentration: 30 mg, Frequency:3 times every 12 hours, Duration: 24 hours. Additional Description: Patch Placement: Hairless areas on the arm or forearm. Intervention 2: Intervention group2:  Name of the drug: Diclofenac, How to use: Skin patch (patches with the trademark Flector EP tissugel from Altergon Italia Srl company), Patch concentration: 1.3 percent Diclofenac epolamine( including 1%diclofenac equal to 15mg), Frequency:3 times every 12 hours, Duration: 24 hours. Additional Description: Patch Placement: Hairless areas on the arm or forearm. Intervention 3: Control group: Name of the drug: Ibuprofen, How to use: Oral tablets (Made by Raha pharmaceutical company), Tablet concentration: 400 mg, Frequency:4 times Every 8 hours, Duration: 24 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data in this study can be shared.

When:
The beginning of the access period is after 1403

To whom:
The data of this study will be available for use by other researchers.

Conditions:
In the case of using the results and methods of this study, the source should be mentioned.

Where to obtain:
Dr. Yasamin Babaee Hemmati, Guilan dental school

How to obtain:
Review and satisfaction of the person responsible for the implementation of this study.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Yasamin Babaee Hemmati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Guilan dental school, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144693358</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>yasi.10482@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Yasamin Babaee Hemmati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Guilan dental school, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144693358</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>yasi.10482@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who want to start fixed orthodontic treatment of 2 jaws.
Patients should be in the age range of 18 to 30 years.
Patients should be healthy in terms of physical condition, without any systemic disease and according to the classification of the American Society of Anesthesiology should be in ASA I group.
Based on Little's Irregularity Index, patients should have 3-6 mm of crowding in both upper and lower jaws and do not need tooth extraction.
Patients should not take any medication at the moment.
Patients should not report a history of bleeding or gastrointestinal discomfort or any allergies after taking Asprin-like drugs such as ibuprofen, and should not have any problems using ketoprofen, diclofenac, and ibuprofen.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who have taken any painkiller within 24 hours before treatment.
Patients who cannot give informed consent.
Patients who are illiterate.
Patients who need restoration, root canal treatment or extraction of their teeth.
Patients who have spontaneous pain in their teeth or periodontal problems do not allow to start orthodontic treatment.
Patients who are pregnant or breastfeeding their babies.
Patients who have a history of liver or kidney diseases or take drugs that affect these 2 organs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1:  Name of the drug: Ketoprofen, How to use: Skin patch (patches with the trademark Kefentech from jeil health science company), Patch concentration: 30 mg, Frequency:3 times every 12 hours, Duration: 24 hours. Additional Description: Patch Placement: Hairless areas on the arm or forearm</i_keyword>
      <i_keyword>Intervention group2:  Name of the drug: Diclofenac, How to use: Skin patch (patches with the trademark Flector EP tissugel from Altergon Italia Srl company), Patch concentration: 1.3 percent Diclofenac epolamine( including 1%diclofenac equal to 15mg), Frequency:3 times every 12 hours, Duration: 24 hours. Additional Description: Patch Placement: Hairless areas on the arm or forearm</i_keyword>
      <i_keyword>Control group: Name of the drug: Ibuprofen, How to use: Oral tablets (Made by Raha pharmaceutical company), Tablet concentration: 400 mg, Frequency:4 times Every 8 hours, Duration: 24 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity after initial arch wire placement in orthodontic patients. Timepoint: Immediately after arch wire placement and 2, 6 hours later, while sleeping, 24, 48 hours, 3 and 7 days after treatment. Method of measurement: Numerical rating scale (NRS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-31</approval_date>
        <contact_name>Research Ethics Committees of Guilan university of medical sciences</contact_name>
        <contact_address>No. 20, Faraz building, Fajr Alley, Namjoo Ave Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
